Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4H7D5)

Drug Name

PHA-767491 Drug Info

Synonyms

PHA-767491; 845714-00-3; PHA 767491; CAY10572(PHA-767491); PHA-767491 (CAY10572); 2-Pyridin-4-yl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one; 1,5,6,7-Tetrahydro-2-(4-pyridinyl)-4H-pyrrolo[3,2-c]pyridin-4-one; Pyrrolopyridinone, 1; Cdc7/Cdk9 Inhibitor; Kinome_2973; JMC502647 Compound 8; MLS006011036; SCHEMBL4767679; GTPL8763; CHEMBL225519; CTK8F8505; CHEBI:95058; BDBM27344; DTXSID50471069; MolPort-009-019-436; HMS3656P19; HMS3229B21; BCP02855; PHA-767491A; PHA767491; ZINC16052718; s2742; 2651AH; AKOS026674124; SB19465; CS-1208

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 11715767
ChEBI ID: CHEBI:95058
CAS Number: CAS 845714-00-3
TTD Drug ID: DM4H7D5

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting CDC7-related kinase (CDC7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BMS-863233	DM5HUY8	Haematological malignancy	2B33.Y	Phase 1/2	[2]
TAK-931	DM1ALY9	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
PMID26161698-Compound-44	DM8UPO3	N. A.	N. A.	Patented	[4]
PMID19115845C89S	DMB9F2L	Discovery agent	N.A.	Investigative	[5]
PMID20873740C18	DMVHR3Z	Discovery agent	N.A.	Investigative	[6]
PMID24793884C74	DMFSJQC	Discovery agent	N.A.	Investigative	[7]
PMID24793884C77	DMZENGX	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CDC7-related kinase (CDC7)	TTSMTDI	CDC7_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	Drug design with Cdc7 kinase: a potential novel cancer therapy target. Drug Des Devel Ther. 2009 Feb 6;2:255-64.
2	Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
5	First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
6	Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem. 2010 Oct 28;53(20):7296-315.
7	Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem. 2014 Jun 10;80:364-82.